Levetiracetam Arena (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This binding modulates synaptic transmission, decreasing neuronal hyper‑excitability and preventing the abnormal electrical discharges that cause seizures.

The dosage of Levetiracetam Arena is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type and response to therapy. Only a qualified healthcare professional should set the appropriate dose and schedule.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against possible risks and discuss options with the patient. If used, close monitoring is recommended, and breastfeeding decisions should consider drug exposure through milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well‑tolerated, has fewer drug‑enzyme interactions, and can be used as monotherapy or adjunctive therapy depending on seizure type.

Levetiracetam Arena should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Levetiracetam Arena is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with water and the dosing schedule (once, twice or multiple times daily) is individualized for each patient.

Serious risks include rare but severe skin reactions (e.g., Stevens‑Johnson syndrome), suicidal thoughts or behaviors, major depressive episodes, and hypersensitivity reactions such as anaphylaxis. Patients should be instructed to seek immediate medical attention if they notice any of these symptoms.

Levetiracetam Arena is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting anticonvulsants that markedly reduce its effectiveness.